Collplant Biotechnologies Ltd. · NASDAQ:CLGN
Collplant Biotechnologies — Investor Presentation (February 2021)
27 slides from Collplant Biotechnologies's investor presentation, Feb 8, 2021
Slide 1: CollPlant Overview
CollPlant Overview Gf CollPlant er X Biotechnologies | Medicine February 2021 ‘
Slide 2: Safe Harbor Statement
Safe Harbor Statement Certain statements in this presentation constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act and Section 21£ of the Securities Exchange Act and are usually identified by the use of words such as "anticipates," "believes," "estimates,"
Slide 3: CollPlant overview
CollPlant overview Medical Aesthetics 3D Bioprinting A regenerative and aesthetic medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing eZ Proprietary technology platform that enables mass production of recombinant human collagen —ahi (rhCol
Slide 4: Experienced management team
Experienced management team Yehiel Tal CEO Regentis Biomaterials Eran Rotem Deputy CEO & CFO Tefron, CFO (NYSE,TASE) Prof. Oded Shoseyov Co-Founder & Chief Scientist Pauli Clean Tech CBD Tech. ProChon Biotech Healthcare Tech., CFO Fulcrum-SPD Kulicke & Soffa Industries (NASDAQ) & Gamida Melodea E&Y
Slide 5: Board of directors
Board of directors Dr. Avri Havron Board member Kamada PROLOR Biotech (acquired by Opko Health) Clal Biotechnology Industries BioTechnology General Interpharm Laboratories Dr. Elan Penn Board member A.l. Research and Development Sivan Computer Training Company Mashov Computers Magic Software Enterpr
Slide 6: Transgenic tobacco plants
Transgenic tobacco plants Expressing 5 human genes
Slide 7: Large scale human collagen produced in tobacco plants
Large scale human collagen produced in tobacco plants rhCollagen production process | Products | Growing Extraction Purification Medical aesthetics Transgenic tobacco Crude extract rhCollagen
Slide 8: Plant-derived
Plant-derived »_ Cell binding domains ity » Accelerates human cell proliferation » Faster tissue healing Better bio-func perior homogeneity e Controlled physical/rheological properties e Reproducibility e Transparency (not visible) Improved safety and greater Non-immunogenic Non-allergenic e No path
Slide 9: Product Pipeline
Product Pipeline F colPiant Aesthetic medicine -----------; 3D bioprinting Dermal/soft tissue fillers / 3D bioprinted products BioInk formulations Collaboration with Photocurable Injectable breast Breast implants Soft and hard ° dermal filler* implants* tissues * Allergan : an AbbVie company Lung an
Slide 10: 3D Bioprinted Tissues and Organs
(J 7 3D Bioprinted | Tissues and Organs
Slide 11: Critical need for organs
oply lica al need f rgans US transplants per year 3D bioprinting expected to bridge this gap and allow unlimited supply of life saving organs US waiting list The technological building blocks already exist — —_ a system integrator is an raya 900,000 needed to assemble US deaths per year from them al
Slide 12: 3D Bioprinting Major Segments
3D Bioprinting Major Segments Representing a Multi- Billion Dollar Market Opportunity Organs | Endocrineglands ; Tissues | Scaffolds : Drug discovery e Lungs ' e Ovary ' e Breast ' e Spine fusion ' e Mimic pathologic e Kidney ' e Pancreas ' @ Skin ' © Non-union fractures! ssa (slitetey e Liver ! @ T
Slide 13: rhCollagen BioInk
rhCollagen Biolnk Compositions in development (with partners/collaborators) ECM components (biological/ physical properties) Direct Ink Writing (DIW) ———o ———= Polymers ———° (physical properties) : f * GfcoltPlan Ceramics ; Biolnk : o____ Projection (hard tissue) pau. . Stereolithography REnepartiel
Slide 14: Collaboration agreement with United Therapeutics (2018)
Collaboration agreement with United Therapeutics (2018) * Global licensing and commercialization Agreement highlights: agreement for 3D Bioprinting of solid organ - $5M upfront payment scaffolds for human transplants » Up to $39M milestone and option payments A . , . » Royalties on product sales * C
Slide 15: 3D bioprinting examples
3D bioprinting examples —— Organ | Soars Manufacturing} 3D bioprinting of trachea using CollPlant’s BioInk. Bioprinting of soft tissue implant Courtesy of United Therapeutics
Slide 16: 3D Systems and CollPlant Biotechnologies Join Forces
3D Systems and CollPlant Biotechnologies Join Forces to Accelerate Breakthroughs in Regenerative Medicine ° 3D bioprinted soft tissue implant with vascularization channels perfused with red ink ° The implant was printed using 3D Systems’ high resolution bioprinter and BioInk that is based on CollPla
Slide 17: Breast implants
Breast implants coliPlant Pere genre Mako
Slide 18: Breast implants market overview
Breast implants market overview Current breast reconstruction is based on synthetic breast implantation, free flap surgery/autologous fat tissue transfer - all of which replace tissue rather than regenerate it. re) $1.4B Market Procedure (us segmentation) worldwide (2018)! = Breast augmentation = Br
Slide 19: CollPlant's 3D bioprinted breast implants
CollPlant’s 3D bioprinted breast implants Breast scaffold bioprinting ECM components + Implantation and Implant replacement by autologous fat cells loading vascularization newly formed tissue
Slide 20: Dermal/Soft tissue fillers
Dermal/Soft tissue fillers F collPlant Pret genre Mako
Slide 21: Dermal fillers market overview
Dermal fillers market overview AY CTSRCEhT ee ee IS (by material)* aime NUL ~2,160,578 HA procedures in 2019 in the US! 8.2% >$6.2B, 7.6% CAGR Global dermal filler market, 20192 CAGR 2020-2026? @ Hyaluronic acid ™@ Calcium Hydroxylapatite $100-$250/unit mPRP j 3. Cost per syringe ™ Polylactic acid F
Slide 22: Collaboration agreement with AbbVie (Feb. 2021)
Collaboration agreement with AbbVie (Feb. 2021) * A worldwide exclusive development and Agreement highlights: commercialization agreement for dermal and soft tissue » Up to $103M in potential payments, including: » §14M upfront payment » Up to $89 milestones and option payments * Combines CollPlant’
Slide 23: Photocurable regenerative dermal filler key attributes
rhCollagen-based Photocurable regenerative dermal filler key attributes Easy injection Sculpting before Optimized post Good tissue (30G needle) curing curing stiffness retention Injection Sculpting Photocuring in-situ Tissue regeneration
Slide 24: Injectable breast implants
Injectable breast implants* * Composed of rhCollagen, additional materials and fat cells taken from the patient ¢ Intended to promote breast tissue regeneration ¢ Designed to support the viability and function of the autologous fat cells, and to attract cells to promote tissue regeneration ° The sca
Slide 25: CollPlant Pioneering Regenerative Medicine
_— P CollPlant Pioneering . . Regenerative SN Biotechnologies | Medicine 51 employees NASDAQ (CLGN), NASDAQ listed since Jan 2018 ooo 4M UD) Strong R&D team Revenue (ttm*): $6.02M {O} Fully integrated Market Cap: {os $118M* Production team Ave vol (3m): with proven track 41k shares record 5) CollPla
Slide 26: CollPlant investment highlights
CollPlant investment highlights Only commercially viable technology currently available that can produce truly human collagen Multi-billion dollar market: innovative rhCollagen products initially aimed at 3D bioprinting and medical aesthetics Broadly applicable technology: Ideal building block/scaff
Slide 27: Thank you
ff CollPlant 2, Xx Biotechnologies | Medicine i Thank you
CollPlant Biotechnologies — Investor Presentation (February 2021) on 6ix